Nemucore Medical Innovations, Inc.

Nemucore Medical Innovations, Inc. is a biopharmaceutical company founded in 2008 with a mission to revolutionize cancer treatment. The company's vision is to provide effective drugs to cancer patients from the first treatment. Their drug, NMI-900, is developed for the 70% of patients who do not have the DNA mutations that indicate favorable responses to certain drugs. Their innovative approach involves combining NMI-900 with a unique diagnostic that measures RNA, offering the potential to select the right patient, improve survival rates, and minimize side effects. In 2015, Nemucore Medical Innovations received a significant Series A investment. Their focus on biopharma, biotechnology, and healthcare has positioned them as a key player in the health and wellness industry. The company's headquarters are located in the United States. With plans for regulatory approval in Acute Myeloid Leukemia (AML) within the next five years, Nemucore Medical Innovations aims to make a meaningful impact on cancer treatment. For more information, visit their profile on Wefunder.